# Home Based Daratumumab Administration for Patients With Multiple Myeloma

> **NCT05511428** · PHASE4 · COMPLETED · sponsor: **Thomas Jefferson University** · enrollment: 20 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **DRUG:** Daratumumab and Hyaluronidase-fihj
- **OTHER:** Questionnaire Administration
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Interview

## Key facts

- **NCT ID:** NCT05511428
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-08
- **Primary completion:** 2024-05-22
- **Final completion:** 2024-05-22
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05511428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05511428, "Home Based Daratumumab Administration for Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05511428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*